Aroda Vanita R, Getaneh Asqual
a 1 MedStar Health Research Institute, Hyattsville, MD, USA.
b 2 Georgetown University School of Medicine, WA, USA.
Expert Rev Endocrinol Metab. 2015 Jul;10(4):381-398. doi: 10.1586/17446651.2015.1054280. Epub 2015 Jun 16.
Advances made in diabetes management are not sufficient to reduce morbidity, mortality and cost without making prevention efforts at various levels imperative for substantial impact. Research has demonstrated the efficacy of lifestyle intervention and medications in preventing type 2 diabetes among diverse high-risk groups commonly identified with oral glucose tolerance testing. Efficacy, sustainability and safety data are most comprehensive for lifestyle and metformin, with other medications also demonstrating efficacy and potential in the pharmacoprevention of diabetes. Subsequent implementation studies have demonstrated feasibility of lifestyle intervention programs at health centers, communities, and at local and national government levels. Challenges remain in widespread translation and reaching and engaging at-risk individuals and populations.
糖尿病管理方面取得的进展不足以降低发病率、死亡率和成本,因此必须在各个层面进行预防工作,才能产生重大影响。研究表明,生活方式干预和药物治疗在预防通过口服葡萄糖耐量试验通常确定的不同高危人群中的2型糖尿病方面具有疗效。生活方式干预和二甲双胍的疗效、可持续性和安全性数据最为全面,其他药物在糖尿病的药物预防方面也显示出疗效和潜力。随后的实施研究表明,生活方式干预项目在健康中心、社区以及地方和国家政府层面是可行的。在广泛推广以及接触和吸引高危个体和人群方面仍然存在挑战。